Gosset research
Reports: Antibody
Gosset reports matching these filters, newest first.
9 items Clear filters
Worked example
Claudin 18.2 competitive landscape
Claudin 18.2 programs from preclinical to approval, with program profiles, trial sources and licensing context.
Worked example
TL1A competitive landscape
TL1A pipeline data, market dynamics, ownership charts and a downloadable spreadsheet.
Research article
Tegoprubart: a CNI-free bet on tolerability in kidney transplant
Eledon’s anti-CD40L antibody missed its Phase 2 efficacy endpoint yet separated sharply from tacrolimus on safety.
- Undated
Landscape
Claudin 18.2 research landscape
Source-linked programs, patient populations, clinical results and rights across antibodies, ADCs and cell therapies.
- Undated
Landscape
TL1A research landscape
TL1A biology in inflammatory bowel disease, the Merck, Roche and Sanofi-Teva Phase 3 race, clinical evidence, patents and deals.
- Undated
Landscape
TSLP research landscape
How tezepelumab set the benchmark in severe asthma and nasal polyps, and the programs testing new dosing, delivery and targets.
- External sample
Report · External · Slide deck
Asset due diligence: Frexalimab for relapsing multiple sclerosis (opens Slide deck on Google Drive)
Full due-diligence assessment of a drug asset: thesis, evidence, competitive landscape, IP, pricing, and risks.
- External sample
Landscape · External · Google Sheets
Competitive landscaping: Anti-TL1A antibodies in inflammatory bowel disease (opens Google Sheets on Google Drive)
Every drug targeting a given target or modality, with detailed development status.
- External sample
Report · External · Google Sheets
Head-to-head results: IL-13 vs IL-4Rα biologics in atopic dermatitis (EASI-75, IGA 0/1) (opens Google Sheets on Google Drive)
Side-by-side comparison of trial outcomes for a drug class or indication. Covers safety, efficacy, patient population, and trial design.